Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 18 2023 - 4:05PM
Business Wire
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company
committed to advancing new medicines for patients with cancer,
today announced the grant of 96,700 restricted stock units (RSUs)
to four new employees. The awards were granted pursuant to the
Nasdaq inducement grant exception as an inducement material to the
employees’ acceptance of employment with Verastem Oncology in
accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs that were
granted to the four new employees will vest at a rate of
twenty-five percent (25%) on the one-year anniversary of the
employees’ date of hire, with the remaining shares vesting
quarterly over the next three (3) years in equal quarterly amounts,
provided the employees continues to serve as an employee of or
other service provider to Verastem Oncology on each such vesting
date.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a
development-stage biopharmaceutical company committed to the
development and commercialization of new medicines to improve the
lives of patients diagnosed with cancer. Our pipeline is focused on
novel small molecule drugs that inhibit critical signaling pathways
in cancer that promote cancer cell survival and tumor growth,
including RAF/MEK inhibition and FAK inhibition. For more
information, please visit www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230118005684/en/
Investors:
Dan Calkins Investor Relations +1 781-469-1694
dcalkins@verastem.com
Nate LiaBraaten +1 212-600-1902 nate@argotpartners.com
Media:
Lisa Buffington VP, Corporate Communications +1 781-292-4205
lbuffington@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Jul 2023 to Jul 2024